ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.

Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial investigating the efficacy and safety of lorundrostat in controlling blood pressure for hypertensive patients. Other key outcomes of interest include reductions in systolic and diastolic blood pressure, as well as the tolerability of the drug.

Findings showed that lorundrostat effectively lowered 24 hour blood pressure in patients with well treated uncontrolled and resistant hypertension. A dose escalation strategy from 50 to 100mg did not lower blood pressure more than 50mg, and was associated with higher rates of adverse events.

Recorded Onsite at ACC 25, Chicago.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Oliver Miles

Support: This is an independent interview produced by Radcliffe CVRM.